Sugi Predict

Sugi Predict / Targets / PI4KB

PI4KB

Phosphatidylinositol 4-kinase beta · Q9UBF8 · PI4KB on Sugi Atlas →

72,051 patent compounds predicted against PI4KB, 45,793 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL48678 SCHEMBL48678 0.69 17/20
SCHEMBL48423 SCHEMBL48423 0.68 17/20
SCHEMBL48791 SCHEMBL48791 0.68 17/20
SCHEMBL49055 SCHEMBL49055 0.62 17/20
SCHEMBL48463 SCHEMBL48463 0.60 17/20
SCHEMBL48560 SCHEMBL48560 0.60 17/20
SCHEMBL10811 SCHEMBL10811 0.57 15/20
SCHEMBL48522 SCHEMBL48522 0.62 14/20
SCHEMBL48581 SCHEMBL48581 0.58 14/20
SCHEMBL48376 SCHEMBL48376 0.58 14/20
SCHEMBL48790 SCHEMBL48790 0.61 13/20
SCHEMBL48438 SCHEMBL48438 0.61 13/20
SCHEMBL49489 SCHEMBL49489 0.59 13/20
SCHEMBL48666 SCHEMBL48666 0.57 12/20
SCHEMBL9010 SCHEMBL9010 0.54 12/20
SCHEMBL48483 SCHEMBL48483 0.57 11/20
SCHEMBL48700 SCHEMBL48700 0.52 11/20
SCHEMBL11830 SCHEMBL11830 0.48 11/20
SCHEMBL48677 SCHEMBL48677 0.76 10/20
SCHEMBL48422 SCHEMBL48422 0.64 10/20

Clinical trials — most relevant to PI4KB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial PHASE2/PHASE3UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Curcumin in Combination With Chemotherapy in Advanced Breast Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia PHASE2WITHDRAWN
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PI4KB binder may also engage these)

ProteinNameSimilarity
B0KWC1 — 1.000 B0KWC1 →
B1MTG7 — 1.000 B1MTG7 →
B2KI64 — 1.000 B2KI64 →
O02810 — 1.000 O02810 →
O08561 — 1.000 O08561 →
B3EX61 — 1.000 B3EX61 →
A4IID4 — 1.000 A4IID4 →
B4UT09 — 1.000 B4UT09 →
A9X1A0 — 1.000 A9X1A0 →
Q8BKC8 — 1.000 Q8BKC8 →
Q6GN16 — 1.000 Q6GN16 →
Q49GP3 — 1.000 Q49GP3 →
Q8CI95 — 0.986 Q8CI95 →
Q9BXB4 — 0.985 Q9BXB4 →
Q641K1 — 0.985 Q641K1 →
P70531 — 0.983 P70531 →
Q9UPW5 — 0.983 Q9UPW5 →
Q6F6B3 — 0.982 Q6F6B3 →
EEF2K Eukaryotic elongation factor 2 kinase 0.982 landscape →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.981 landscape →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 0.981 landscape →
Q07139 — 0.981 Q07139 →
Q8K4S7 — 0.980 Q8K4S7 →
Q8WXG6 — 0.980 Q8WXG6 →
Q62136 — 0.979 Q62136 →
P31266 — 0.979 P31266 →
Q69ZT9 — 0.979 Q69ZT9 →
Q99JP0 — 0.979 Q99JP0 →
B2RQE8 — 0.979 B2RQE8 →
Q5R585 — 0.979 Q5R585 →